00239.HK
Pak Fah Yeow International Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · HK
HKD 2.50
−0.79%Year over year
Reported trailing growth
- Revenue
- -13.1%
- EBITDA
- -11.0%
- EBIT
- -11.1%
- EPS
- -6.8%
- Free cash flow
- -57.4%
- Operating cash flow
- -57.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +13.3%
- EBITDA
- +36.0%
- EBIT
- +33.3%
- Net income
- +45.0%
- EPS
- +44.5%
- Free cash flow
- +41.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026